Antineoplastics and Immunomodulators 2026-Ii Tender

• Country: Czech Republic
• Summary: Antineoplastics and Immunomodulators 2026-Ii
• CZT Ref No: 139883806
• Deadline: 22 May 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: CZK 3376000
• Notice Type: Tender
• Document Ref. No.: 272941-2026
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Cytostatic drug containing the active ingredient avapritinib Immunopreparation containing the active substance rituximab Immunosuppressant containing the active ingredient apremilast Immunosuppressant containing the active substance baricitinib Cytostatic drug containing the active substance fruchintinib Cytostatic with containing the active substance fludarabine Immunosuppressant containing the active substance ublituximab Cytostatic agent containing the active substance amivantamab Cytostatic drug containing the active substance carmustine Cytostatic drug containing the active ingredient abemaciclib Immunosuppressant containing rabbit antithymocyte immunoglobulin Cytostatic drug containing the active substance nintedanib Cytostatic drug containing the active substance idelalisib The subject of the public contract is the supply of medicinal products intended for the therapy of serious chronic diseases in general expected volume of 516,688 individual doses of medicinal products. The preparations are intended for the provision of health care at the medical workplaces of the FN Plzeň.. Deliveries of the subject of performance will be carried out based on the results of the completed procurement procedure after for a period of four years from the signing of the purchase contract. After. form containing 25 mg of avapritinib per form unit, estimated annual volume of 240 form units (doses); after. form containing 100 mg of avapritinib per form unit, expected annual volume of 240 form units (dose); after. form containing 300 mg of avapritinib per form unit, expected annual volume of 120 form units (doses); ATC L01EX18 Ampoules containing 100 mg of rituximab, expected annual volume of 1,780 ampoules...
• Documents:

 Tender Notice